Literature DB >> 20079667

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Paul A Blair1, Lina Yassin Noreña, Fabian Flores-Borja, David J Rawlings, David A Isenberg, Michael R Ehrenstein, Claudia Mauri.   

Abstract

The immunosuppressive function of regulatory B cells has been shown in several murine models of chronic inflammation, including collagen-induced arthritis, inflammatory bowel disease, and experimental autoimmune encephalomyelitis. Despite interest in these cells, their relevance to the maintenance of peripheral tolerance in humans remains elusive. Here, we demonstrate that human CD19(+)CD24(hi)CD38(hi) B cells possessed regulatory capacity. After CD40 stimulation, CD19(+)CD24(hi)CD38(hi) B cells suppressed the differentiation of T helper 1 cells, partially via the provision of interleukin-10 (IL-10), but not transforming growth factor-beta (TGF-beta), and their suppressive capacity was reversed by the addition of CD80 and CD86 mAbs. In addition, CD19(+)CD24(hi)CD38(hi) SLE B cells isolated from the peripheral blood of systemic lupus erythematosus (SLE) patients were refractory to further CD40 stimulation, produced less IL-10, and lacked the suppressive capacity of their healthy counterparts. Altered cellular function within this compartment may impact effector immune responses in SLE and other autoimmune disorders. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20079667     DOI: 10.1016/j.immuni.2009.11.009

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  564 in total

1.  Pulsed high-dose dexamethasone improves interleukin 10 secretion by CD5+ B cells in patients with primary immune thrombocytopenia.

Authors:  Fanli Hua; Lili Ji; Yanxia Zhan; Feng Li; Shanhua Zou; Xiaoyun Wang; Dongli Song; Zhihui Min; Song Gao; Yangjiong Wu; Hao Chen; Yunfeng Cheng
Journal:  J Clin Immunol       Date:  2012-06-06       Impact factor: 8.317

2.  Interleukin-10 receptor expression and signalling were down-regulated in CD4⁺ T cells of lupus nephritis patients.

Authors:  H D Cui; Z M Qi; L L Yang; L Qi; N Zhang; X L Zhang; S Y Du; Y Jiang
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

Review 3.  Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.

Authors:  A Vossenkämper; P M K Lutalo; J Spencer
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

4.  Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

Authors:  Mayuka Horikawa; Veronique Minard-Colin; Takashi Matsushita; Thomas F Tedder
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

Review 5.  Regulatory immune cells in transplantation.

Authors:  Kathryn J Wood; Andrew Bushell; Joanna Hester
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 6.  Regulatory B cells in autoimmunity: developments and controversies.

Authors:  Claudia Mauri; Paul A Blair
Journal:  Nat Rev Rheumatol       Date:  2010-09-21       Impact factor: 20.543

Review 7.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

8.  [Regulatory B cells and their role in maintaining peripheral tolerance].

Authors:  T Tretter; H-M Lorenz
Journal:  Z Rheumatol       Date:  2010-11       Impact factor: 1.372

Review 9.  The double life of a B-1 cell: self-reactivity selects for protective effector functions.

Authors:  Nicole Baumgarth
Journal:  Nat Rev Immunol       Date:  2010-12-10       Impact factor: 53.106

10.  CD27+TIM-1+ memory B cells promoted the development of Foxp3+ Tregs and were associated with better survival in acute respiratory distress syndrome.

Authors:  Guangfa Zhu; Yan Liu; Wenmei Zhang; Yan Huang; Keng Li
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.